Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Laboratory of Ligand Engineering, Institute of Biotechnology, Czech Academy of Sciences, v.v.i., BIOCEV Research Center, Vestec, Czech Republic.
J Enzyme Inhib Med Chem. 2021 Dec;36(1):914-921. doi: 10.1080/14756366.2021.1906664.
Pathogenic yeasts frequently cause infections in hospitals. Antifungal drugs lose effectiveness due to other species and resistance. New medications are thus required. Secreted aspartic protease of (Sapp1p) is a promising target. We have thus solved the crystal structures of Sapp1p complexed to four peptidomimetic inhibitors. Three potent inhibitors (K: 0.1, 0.4, 6.6 nM) resembled pepstatin A (K: 0.3 nM), a general aspartic protease inhibitor, in terms of their interactions with Sapp1p. However, the weaker inhibitor (K: 14.6 nM) formed fewer nonpolar contacts with Sapp1p, similarly to the smaller HIV protease inhibitor ritonavir (K: 1.9 µM), which, moreover, formed fewer H-bonds. The analyses have revealed the structural determinants of the subnanomolar inhibition of aspartic protease. Because of the high similarity between Saps from different species, these results can further be used for the design of potent and specific Sap inhibitor-based antimycotic drugs.
致病性酵母菌在医院经常引起感染。由于其他物种和耐药性的存在,抗真菌药物的效果降低。因此需要新的药物。分泌的天冬氨酸蛋白酶(Sapp1p)是一个很有前途的靶点。我们已经解决了 Sapp1p 与四种肽拟似物抑制剂复合物的晶体结构。三种有效的抑制剂(K:0.1、0.4、6.6 nM)与天冬氨酸蛋白酶抑制剂 Pepstatin A(K:0.3 nM)在与 Sapp1p 的相互作用方面相似。然而,较弱的抑制剂(K:14.6 nM)与 Sapp1p 形成的非极性接触较少,与较小的 HIV 蛋白酶抑制剂利托那韦(K:1.9 µM)相似,此外,形成的氢键较少。分析揭示了 Sapp1p 天冬氨酸蛋白酶亚纳摩尔抑制的结构决定因素。由于不同物种的 Saps 之间具有高度的相似性,因此这些结果可进一步用于设计强效和特异性 Sap 抑制剂抗真菌药物。